Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats

被引:15
作者
Dupuis, A
Couet, W
Paquereau, J
Debarre, S
Portron, A
Jamois, C
Bouquet, S
机构
[1] Fac Med & Pharm, Lab Biopharm, F-86005 Poitiers, France
[2] CHU La Miletrie, Lab Pharmacocinet, F-86021 Poitiers, France
[3] Fac Med & Pharm, Physiol Lab, F-86005 Poitiers, France
关键词
D O I
10.1128/AAC.45.6.1682-1687.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A pharmacokinetic-pharmacodynamic (PK-PD) modeling approach was developed to investigate the epileptogenic activity of imipenem in rats. Initially, animals received an intravenous infusion of imipenem at a rate of 2.65 mg min(-1) for 30 min. Blood samples were collected for drug assay, and an electroencephalogram (EEG) was recorded during infusion and postinfusion. A dramatic delay was observed between concentrations of imipenem in serum and the EEG effect; this effect was accompanied by tremors and partial seizures. Indirect-effect models failed to describe these data, which were successfully fitted using an effect compartment model. The relationship between effect and concentration at the effect site was best described by a spline function. The elimination rate constant from the effect compartment was severalfold lower than that from the central compartment. The robustness of the model was then confirmed after administering the imipenem dose over 60 and 90 min. In conclusion, the successful PK-PD modeling of the imipenem EEG effect in rats constitutes a major improvement for better prediction of the epileptogenic risk associated with this antibiotic.
引用
收藏
页码:1682 / 1687
页数:6
相关论文
共 41 条
[1]   FACTORS PREDISPOSING TO SEIZURES IN SERIOUSLY ILL INFECTED PATIENTS RECEIVING ANTIBIOTICS - EXPERIENCE WITH IMIPENEM-CILASTATIN [J].
CALANDRA, G ;
LYDICK, E ;
CARRIGAN, J ;
WEISS, L ;
GUESS, H .
AMERICAN JOURNAL OF MEDICINE, 1988, 84 (05) :911-918
[2]   REVIEW OF ADVERSE EXPERIENCES AND TOLERABILITY IN THE 1ST 2,516 PATIENTS TREATED WITH IMIPENEM CILASTATIN [J].
CALANDRA, GB ;
BROWN, KR ;
GRAD, LC ;
AHONKHAI, VI ;
WANG, C ;
AZIZ, MA .
AMERICAN JOURNAL OF MEDICINE, 1985, 78 (6A) :73-78
[3]   THE SAFETY PROFILE OF IMIPENEM CILASTATIN - WORLDWIDE CLINICAL-EXPERIENCE BASED ON 3470 PATIENTS [J].
CALANDRA, GB ;
WANG, C ;
AZIZ, M ;
BROWN, KR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 :193-202
[4]   DETERMINATION OF IMIPENEM IN HUMAN PLASMA, URINE AND TISSUE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
CARLUCCI, G ;
BIORDI, L ;
VICENTINI, C ;
BOLOGNA, M .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (03) :283-286
[5]   CENTRAL-NERVOUS-SYSTEM TOXICITY OF QUINOLONES - HUMAN AND ANIMAL FINDINGS [J].
CHRIST, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 :219-225
[6]  
Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095
[7]  
DANHOF M, 1984, J PHARMACOL EXP THER, V229, P44
[8]   CORRELATION BETWEEN IN-VITRO AND IN-VIVO MODELS OF PROCONVULSIVE ACTIVITY WITH THE CARBAPENEM ANTIBIOTICS, BIAPENEM, IMIPENEM-CILASTATIN AND MEROPENEM [J].
DAY, IP ;
GOUDIE, J ;
NISHIKI, K ;
WILLIAMS, PD .
TOXICOLOGY LETTERS, 1995, 76 (03) :239-243
[9]   COMPARISON OF 4 BASIC MODELS OF INDIRECT PHARMACODYNAMIC RESPONSES [J].
DAYNEKA, NL ;
GARG, V ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (04) :457-478
[10]  
Della Paschoa OE, 1998, J PHARMACOL EXP THER, V284, P460